EDRN Prostate MRI Biomarker Study for Prostate Cancer
This study is looking at how well prostate MRI (magnetic resonance imaging) works compared to, or in addition to, standard lab tests like PSA (prostate-specific antigen) in men who might have prostate cancer. Researchers want to see if adding an MRI can help doctors better identify significant prostate cancer. You might be able to join if you are a man, 18 or older, and are scheduled for a prostate biopsy because doctors suspect you have prostate cancer. The main goal is to see if adding an MRI can improve the accuracy of detecting high-grade prostate cancer by 10% over two years. The study's current status is unclear.
- Study design
- This is an observational study planning to enroll 950 men. It compares prostate MRI with laboratory biomarkers.
- What's involved
- You would need to have a prostate MRI and provide blood and urine samples. You must also be scheduled for a prostate biopsy as part of your routine care.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome of clinically significant prostate cancer will be measured at 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
EDRN Prostate MRI Biomarker Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- John T Wei, MD, MS · PRINCIPAL_INVESTIGATOR · University of Michigan
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Clinically significant prostate cancer2 years
Pathologic diagnosis of prostate cancer with at least Gleason 7 or worse cancer grade on a needle biopsy